Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy

NCT01353469 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

485

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Insulin human/Insuman Comb 25 (HR1799)
DRUG: Insulin human/Novolin® 30R

Sponsor

Sanofi